Proactive Investors - Run By Investors For Investors

Immuron deals itself into influenza treatment market, with global pharma company

Immuron deals itself into influenza treatment market, with global pharma company

ASX listed drug developer, Immuron (ASX: IMC) has dealt itself very firmly into the high profile, and potentially high return influenza treatment market.

Immuron has entered into discussions with a top-25 global pharmaceutical company, with a potential joint development of Immuron’s influenza treatment and prevention product.

As indicated previously, Immuron has achieved very positive results in pre-clinical (animal) trials on its influenza product.

Clearly, this is an important step in the evolution of Immuron as it scientifically and commercially progresses its new influenza product.

Immuron is continuing to attract interest in assisting with the scientific development and commercialisation of products from its pipeline.

View full IMC profile View Profile

Immuron Ltd Timeline

June 08 2017
May 30 2017

Related Articles

Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
November 23 2018
The Australian regenerative medicine company is developing a portfolio of innovative cellular therapies targeting significant unmet medical needs with a licence-driven strategy.
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use